Michael Michaud's  Instablog

Michael Michaud
Send Message
Michael Michaud is the founder of Invest2Success.com (http://www.invest2success.com/) and the Invest2Success Blog (http://invest2success.blogspot.com/). He has been investing and trading in the financial markets since 1989. He founded Invest2Success.com to empower individual institutional... More
My company:
My blog:
Invest2Success Blog
  • Glaxo Faces Trouble In China 0 comments
    Jul 21, 2013 7:50 PM | about stocks: GSK, MRK, NVS, PFE, AMGN, BIIB, GILD, TMO


    Glaxo Faces Trouble in China by Zacks Equity Research - By Zacks Investment Research

    GlaxoSmithKline (NYSE:GSK) recently responded to investigations and charges of fraudulent behavior and ethical misconduct leveled by Chinese government authorities. The company will extend its support to the authorities in the course of the investigations and will take all necessary action.

    Meanwhile, the company is taking a number of steps to address the issue including review of all third party agency relationships and compliance procedures in China. Glaxo will also review all transactions related to travel agency use and stop the use of travel agencies identified to date in the investigation.

    We note that the Emerging Markets and Asia Pacific (EMAP) market - of which China is a part - contributed more than 25% of Glaxo's revenues in 2012. Glaxo's revenues from China increased 17% in 2012 as compared to the prior year. We believe that any strict action enforced by the Chinese government will significantly impact Glaxo's top-line.

    Glaxo currently holds a Zacks Rank #3 (Hold). The biggest near-term challenge for Glaxo will be to replace the revenues that will be lost to generic competition. Products like Valtrex, Lamictal, Imitrex, Requip, Combivir and Epivir are already facing declining sales due to intense generic competition. Going forward, a major part of Glaxo's revenues will be exposed to generic competition as products like Pandemrix and Prepandrix are all scheduled to lose exclusivity in the next few quarters.

    We believe that the pipeline at Glaxo must deliver to counter the generic threat. We are impressed by Glaxo's growth-by-acquisition strategy to combat the loss of revenues due to genericization of key products.

    Companies that currently look more attractive include Jazz Pharmaceuticals (NASDAQ:JAZZ), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Cadence Pharmaceuticals Inc. (CADX), carrying a Zacks Rank #1 (Strong Buy).

    Click the Links Below to Review China Hong Kong Markets Investing Advisory Services

    Profit Rocket

    Invest2Success China Hong Kong "Profit Rockets" Stock Picks
    Subscription Email Service

    Free Trial - Receive daily low-risk high-reward stock picks every day that include buy entry, stop-loss, take profit area targets, and trade management information on China and Hong Kong equities to your email.

    Morningstar Asia

    Morningstar Asia Investment Research Free Trial

    Asia Pacific Financial Forecast

    Asian-Pacific Financial Forecast

    Asia-Pacific Markets

    Elliott Wave Intraday Forecasts on the Hang Seng, Nikkei 225, MSCI Singapore, ASX 200, STI, Kospi 200, MSCI Taiwan Stocks


    ZuluTrade Forex Accounts from Multiple Brokers All with Free Buy Sell Signals
    Autotrade the Forex market like never before! Let ZuluTrade drive trades by specialists into your FX account for free. ZuluTrade bridged the gap between valuable information in money markets and trade execution, by converting the advice of professional and talented traders globally to an executed trade rapidly and automatically in your account.

Back To Michael Michaud's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.